Top Medical News
Systemic interventions boost smoking cessation after heart attack
9 hours ago
A systematic implementation of evidence-based interventions helps improve smoking cessation in postmyocardial infarction (MI) patients, a recent study has found.
Upper extremity DVT common in COVID-19 despite proper prophylaxis
About 10 percent of patients with the coronavirus disease 2019 (COVID-19) will suffer from upper extremity deep vein thrombosis despite adequate prophylaxis, a recent study has found.
OSA severity tied to interarm SBP difference
Moderate to severe obstructive sleep apnoea (OSA) shows an independent association with the interarm systolic blood pressure (SBP) difference (IAD), but not with interankle SBP difference (IAND) and ankle-brachial index (ABI), suggests a study.
Tranexamic acid ups blood control after CABG, but aggravates perioperative myocardial infarction
2 days ago
While tranexamic acid improves blood control after coronary artery bypass graft (CABG) surgery, it increases the risk of perioperative myocardial infarction, a recent study has found.
Pregnancy-induced hypertension linked to subsequent arrhythmia
2 days ago
Women with pregnancy-induced hypertension are at increased risk of developing arrhythmia, but not lethal arrhythmias, within 1 year after delivery, a study reports.
Sodium intake amount directly related to overall death risk
2 days ago
Increased levels of dietary sodium (Na) intake and load (Na-L) appear to cause arterial stiffness, a preclinical measure of cardiovascular disease (CVD), in children and young adults, according to a study.
Elevated homocysteine level ups mortality risk in hypertensive adults
2 days ago
The interaction of hypertension and total plasma homocysteine (tHcy) levels contributes to the risk of all-cause mortality among middle-aged and older adults, a US study has found. In addition, hypertension may boost the ability of elevated tHcy to aggravate this risk.
Special Reports
Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?
02 Nov 2021
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]
Product Highlight - Lixiana
29 Sep 2021
Edoxaban 30 mg and 60 mg FC tab
Product Highlight - VIACORAM
16 Jun 2021
Perindopril arginine 3.5 mg,
Amlodipine besilate 2.5 mg tab
Trimetazidine new formulation redefining angina control in daily practice
12 Mar 2021
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Conference Reports
Coffee good – or bad – for the heart
Elvira Manzano, 20 Dec 2021
Daily coffee intake is tied to increased physical activity and incidence of premature ventricular contractions (PVCs) but fewer episodes of supraventricular tachycardia (SVT) and less nighttime sleep in the CRAVE* trial.
Dabigatran or warfarin: Choice does not matter in GIRAF
Elvira Manzano, 16 Dec 2021
The choice of oral anticoagulant does not appear to influence the outcome in terms of preserving cognitive function in older patients with atrial fibrillation (AF), the GIRAF* study has shown.
No penalty to early CABG after stopping ticagrelor
Pearl Toh, 11 Dec 2021
Undergoing CABG* within 2 to 3 days after stopping the antiplatelet ticagrelor does not increase the risk of severe/massive bleeding compared with delaying surgery until 5 to 7 days of ticagrelor discontinuation in patients with ACS**, according to the RAPID CABG *** study presented at AHA 2021.
Low-dose aspirin does not stave off dementia
Roshini Claire Anthony, 10 Dec 2021

A daily 100 mg dose of aspirin for 7 years did not reduce the risk of dementia in individuals with diabetes and no history of cardiovascular disease (CVD), according to results of the ASCEND* study presented at AHA 2021.

Evinacumab reduces LDL-C levels in homozygous FH
Elaine Soliven, 09 Dec 2021
Treatment with evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C) levels in adolescents and adults with homozygous familial hypercholesterolaemia (FH), according to a study presented at AHA 2021.
Empagliflozin beneficial and well tolerated in acute heart failure
Christina Lau, 06 Dec 2021

Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.

Canagliflozin improves HF symptoms, QoL regardless of diabetes status
Pearl Toh, 04 Dec 2021
The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.